Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip

• Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease …
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1

Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr

• Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstiti…
• https://x.com/RichardPAConway/status/1858261329993212326/photo/1

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

• Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Rando…
• https://x.com/RichardPAConway/status/1858251010788991334/photo/1

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT

• Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar…
• https://x.com/RichardPAConway/status/1858242203380003024/photo/1

A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA. @RheumNow https://t.co/ospR0qEIsd

• Apremilast Benefits and Risks in PsA | RheumNow

de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX

• https://x.com/RichardPAConway/status/1858227355447378085/photo/1

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1
• https://x.com/EBRheum/status/1858214520612917751/photo/1

Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR

• https://x.com/Dr_Brian_MD/status/1858215429992517954/photo/1

Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj

• Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide w…
• https://x.com/RichardPAConway/status/1858216031858078047/photo/1